Pathway Analysis of Cell Culture Phenotypes and Uses Thereof

• US 20090186358A1
• Filed: 12/19/2008
• Published: 07/23/2009
• Est. Priority Date: 12/21/2007
• Status: Abandoned Application

• Current Assignee: Dublin City University, Wyeth (Pfizer Inc.)
• Original Assignee: Dublin City University, Wyeth (Pfizer Inc.)
• Inventors: Gammell, Patrick, Doolan, Padraig, Melville, Mark, Clynes, Martin, Barron, Niall, Meleady, Paula
• Application Number:
  US12/340,629
• Publication Number:
  US 20090186358A1
• Time in Patent Office: Days
• US Class Current: 435/6
• CPC Class Codes: C12P 21/02 having a known sequence of two or more amino acids, e.g. glutathione

Abstract

The present invention provides methods for systematically identifying genes, proteins and/or related pathways that regulate or indicative of cell phenotypes. The present invention further provides methods for manipulating the identified genes, proteins and/or pathways to engineer improved cell lines and/or to evaluate or select cell lines with desirable phenotypes.

Claims

1. An engineered cell line characterized by an improved cell culture phenotype as compared to the corresponding wild type or parental cell line comprising a population of engineered cells, each of which comprising an engineered construct up-regulating or down-regulating one or more genes or proteins selected from Tables 1-35, wherein said up-regulating or down-regulating one or more genes or proteins confers the improved cell culture phenotype.

2. The engineered cell line of claim 1, wherein the improved cell culture phenotype is selected from the group consisting of improved peak cell density, improved cell growth rate, improved sustained high cell viability, improved maximum cellular productivity, improved sustained high cellular productivity, reduced lactate production, reduced ammonia production, and combinations thereof.

3. The engineered cell line of claim 1, wherein the one or more genes or proteins are selected from Tables 10 and 11, and wherein said improved cell culture phenotype is improved peak cell density.

4. The engineered cell line of claim 1, wherein the one or more genes or proteins are selected from Table 12, and wherein said improved cell culture phenotype is improved cell growth rate.

5. The engineered cell line of claim 1, wherein the one or more genes or proteins are selected from Tables 1-9, and wherein said improved cell culture phenotype is improved sustained high cell viability.

6. The engineered cell line of claim 1, wherein the one or more genes or proteins are selected from Tables 13-20, and wherein said improved cell culture phenotype is improved maximum cellular productivity.

7. The engineered cell line of claim 1, wherein the one or more genes or proteins are selected from Tables 21-24, and wherein said improved cell culture phenotype is improved sustained high cellular productivity.

8. The engineered cell line of claim 1, wherein the one or more genes or proteins are selected from Tables 25-30, and wherein said improved cell culture phenotype is reduced ammonium production.

9. The engineered cell line of claim 1, wherein the one or more genes or proteins are selected from Tables 31-35, and wherein said improved cell culture phenotype is reduced lactate production.

14. A method of producing a protein of interest, the method comprising:

providing an engineered cell line of claim 1 that carries a nucleic acid encoding a protein of interest;

culturing the engineered cell line under conditions that allow expression of the protein of interest; and

harvesting the protein of interest.

16. A protein produced using the method of claim 14.

10-13. -13. (canceled)

15. (canceled)

17. A method of improving a cell line, the method comprising modifying one or more pathways selected from FIGS. 1-31.

18. The method of claim 17, wherein the one or more pathways are involved in alanine and aspartate metabolism, glutamate metabolism, or combinations thereof, and wherein the modification confers improved peak cell density as compared to the corresponding unmodified cell line.

19. The method of claim 17, wherein the one or more pathways are involved in G1/S checkpoint regulation, ATM signaling, Eda-A1 signaling, Eda-A2 signaling, p53 signaling, JNK-MAPK signaling pathway, mitochondrial control of apoptosis, Rb tumor suppressor signaling, or combinations thereof, and wherein the modification confers improved maximum cellular productivity as compared to the corresponding unmodified cell line.

20. The method of claim 17, wherein the one or more pathways are involved in synthesis and degradation of ketone bodies, and wherein the modification confers improved cell growth rate as compared to the corresponding unmodified cell line.

21. The method of claim 17, wherein the one or more pathways are involved in synthesis and degradation of ketone bodies, butanoate metabolism, valine, leucine, and isoleucine degradation, Eda-A1 signaling, Eda-A2 signaling, or combinations thereof, and wherein the modification confers reduced ammonia production as compared to the corresponding unmodified cell line.

22. The method of claim 17, wherein the one or more pathways are involved in oxidative phosphorylation, mitochondrial dysfunction, butanoate metabolism, synthesis and degradation of ketone bodies, Eda-A1 signaling, Eda-A2 signaling, or combinations thereof, and wherein the modification confers reduced lactate production as compared to the corresponding unmodified cell line.

23. The method of claim 17, wherein the one or more pathways are involved in citrate cycle, butanoate metabolism, glutathione metabolism, NRF2-mediated oxidative stress response, LPS-IL-1 mediated inhibition of RXR function, synthesis and degradation of ketone bodies, Eda-A1 signaling, Eda-A2 signaling, or combinations thereof, and wherein the modification confers improved sustained high cell viability as compared to the corresponding unmodified cell line.

24. The method of claim 17, wherein the one or more pathways are involved in inositol metabolism, glycolysis, gluconeogenesis, NRF2-mediated oxidative stress response, purine metabolism, or combinations thereof, and wherein the modification confers improved sustained high cellular productivity as compared to the corresponding unmodified cell line.

29. A cell line improved by the method of claim 17.

30. A method of producing a protein of interest, the method comprising:

providing an improved cell line of claim 29 that carries a nucleic acid encoding a protein of interest;

culturing the improved cell line under conditions that allow expression of the protein of interest; and

harvesting the protein of interest.

32. A protein produced using the method of claim 30.

25-28. -28. (canceled)

31. (canceled)

33. A method of evaluating a cell culture phenotype of a cell line, the method comprising:

detecting, in a sample of cultured cells, an expression level of at least one protein or gene selected from Tables 1-35;

comparing the expression level to a reference level;

wherein the comparison is indicative of the cell culture phenotype.

34-40. -40. (canceled)

41. A method of evaluating a cell culture phenotype of a cell line, the method comprising:

determining, in a sample of cultured cells, a signaling strength of at least one pathway selected from FIGS. 1-31;

comparing the signaling strength to a reference;

wherein the comparison is indicative of the cell culture phenotype.